I-Mab (IMAB) Competitors $0.92 -0.03 (-3.17%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends IMAB vs. VALN, FDMT, CCCC, IMMP, CMPS, ACIU, AMLX, ITOS, LFCR, and BNTCShould you be buying I-Mab stock or one of its competitors? The main competitors of I-Mab include Valneva (VALN), 4D Molecular Therapeutics (FDMT), C4 Therapeutics (CCCC), Immutep (IMMP), COMPASS Pathways (CMPS), AC Immune (ACIU), Amylyx Pharmaceuticals (AMLX), iTeos Therapeutics (ITOS), Lifecore Biomedical (LFCR), and Benitec Biopharma (BNTC). These companies are all part of the "pharmaceutical products" industry. I-Mab vs. Valneva 4D Molecular Therapeutics C4 Therapeutics Immutep COMPASS Pathways AC Immune Amylyx Pharmaceuticals iTeos Therapeutics Lifecore Biomedical Benitec Biopharma I-Mab (NASDAQ:IMAB) and Valneva (NASDAQ:VALN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment, community ranking and earnings. Do institutionals & insiders have more ownership in IMAB or VALN? 38.4% of I-Mab shares are owned by institutional investors. Comparatively, 11.4% of Valneva shares are owned by institutional investors. 22.1% of I-Mab shares are owned by company insiders. Comparatively, 14.9% of Valneva shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media prefer IMAB or VALN? In the previous week, Valneva had 5 more articles in the media than I-Mab. MarketBeat recorded 5 mentions for Valneva and 0 mentions for I-Mab. Valneva's average media sentiment score of 0.33 beat I-Mab's score of 0.00 indicating that Valneva is being referred to more favorably in the news media. Company Overall Sentiment I-Mab Neutral Valneva Neutral Which has higher earnings and valuation, IMAB or VALN? Valneva has higher revenue and earnings than I-Mab. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioI-Mab$3.27M22.99-$206.44MN/AN/AValneva$158.54M2.04-$109.78M-$0.13-30.69 Which has more volatility & risk, IMAB or VALN? I-Mab has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, Valneva has a beta of 1.98, meaning that its share price is 98% more volatile than the S&P 500. Do analysts prefer IMAB or VALN? I-Mab presently has a consensus price target of $8.00, suggesting a potential upside of 766.74%. Valneva has a consensus price target of $18.50, suggesting a potential upside of 363.66%. Given I-Mab's higher possible upside, equities research analysts plainly believe I-Mab is more favorable than Valneva.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score I-Mab 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Valneva 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is IMAB or VALN more profitable? I-Mab has a net margin of 0.00% compared to Valneva's net margin of -4.35%. I-Mab's return on equity of 0.00% beat Valneva's return on equity.Company Net Margins Return on Equity Return on Assets I-MabN/A N/A N/A Valneva -4.35%-3.93%-1.42% Does the MarketBeat Community prefer IMAB or VALN? I-Mab received 27 more outperform votes than Valneva when rated by MarketBeat users. Likewise, 64.13% of users gave I-Mab an outperform vote while only 60.38% of users gave Valneva an outperform vote. CompanyUnderperformOutperformI-MabOutperform Votes5964.13% Underperform Votes3335.87% ValnevaOutperform Votes3260.38% Underperform Votes2139.62% SummaryI-Mab beats Valneva on 10 of the 15 factors compared between the two stocks. Ad ProsperityPubCrypto’s hidden gem + greatest crypto bull run in history = $$$?You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.Click Here to get the full details about Crypto’s Hidden Gem Get I-Mab News Delivered to You Automatically Sign up to receive the latest news and ratings for IMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMAB vs. The Competition Export to ExcelMetricI-MabPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$75.23M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E RatioN/A10.5990.0517.18Price / Sales22.99195.801,117.14116.99Price / CashN/A57.1643.0437.86Price / Book0.325.094.784.78Net Income-$206.44M$151.83M$120.31M$225.60M7 Day Performance-7.70%-2.13%-1.92%-1.23%1 Month Performance-2.81%-3.10%11.51%3.36%1 Year Performance-40.83%11.54%30.61%16.60% I-Mab Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMABI-Mab2.5162 of 5 stars$0.92-3.2%$8.00+766.7%-38.9%$75.23M$3.27M0.0034Gap DownHigh Trading VolumeVALNValneva2.1517 of 5 stars$3.82-2.8%$18.50+384.3%-62.2%$310.38M$165.52M-30.23700News CoverageHigh Trading VolumeFDMT4D Molecular Therapeutics2.5905 of 5 stars$6.65+2.3%$42.13+533.5%-66.9%$307.42M$17,000.00-2.28201Analyst ForecastCCCCC4 Therapeutics2.0607 of 5 stars$4.34-0.9%$10.00+130.4%-9.2%$306.36M$33.67M-2.58150Analyst UpgradeNews CoverageGap DownIMMPImmutep1.4184 of 5 stars$2.06-5.5%$8.50+312.6%-13.2%$299.65M$5.14M0.002,021CMPSCOMPASS Pathways2.8262 of 5 stars$4.36+3.3%$33.60+670.6%-47.3%$298.32MN/A-1.92120Positive NewsACIUAC Immune2.4741 of 5 stars$2.97+0.7%$12.00+304.0%-33.8%$293.85M$16.48M-6.41140Positive NewsAMLXAmylyx Pharmaceuticals4.2561 of 5 stars$4.16+1.0%$7.33+76.3%-70.7%$285.16M$196.49M-1.08200Short Interest ↓News CoveragePositive NewsITOSiTeos Therapeutics3.5018 of 5 stars$7.78+1.3%$25.25+224.6%-28.4%$284.24M$35M-2.4490Analyst ForecastLFCRLifecore Biomedical2.9045 of 5 stars$7.70+1.2%$10.00+29.9%+18.7%$283.57M$128.44M97.50690BNTCBenitec Biopharma3.6885 of 5 stars$12.13+3.1%$24.43+101.4%+277.8%$281.66M$80,000.000.0020Analyst Revision Related Companies and Tools Related Companies Valneva Alternatives 4D Molecular Therapeutics Alternatives C4 Therapeutics Alternatives Immutep Alternatives COMPASS Pathways Alternatives AC Immune Alternatives Amylyx Pharmaceuticals Alternatives iTeos Therapeutics Alternatives Lifecore Biomedical Alternatives Benitec Biopharma Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IMAB) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding I-Mab Please log in to your account or sign up in order to add this asset to your watchlist. Share I-Mab With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMAB Stock Alerts